David Allsup
Overview
Explore the profile of David Allsup including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
373
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Molica S, Allsup D
Cancers (Basel)
. 2025 Jan;
17(1.
PMID: 39796746
Chronic lymphocytic leukemia (CLL) treatment has undergone a significant evolution with a shift from historical chemotherapeutic regimens to targeted therapies such as Bruton tyrosine kinase (BTK) and BCL-2 inhibitors. These...
2.
Molica S, Allsup D, Giannarelli D
Am J Hematol
. 2024 Dec;
100(2):334-337.
PMID: 39643600
No abstract available.
3.
Naylor-Adamson L, Price T, Booth Z, Leonard S, Gallo J, Tung L, et al.
J Mater Chem B
. 2024 Dec;
13(3):1052-1063.
PMID: 39635869
Quantum dots (QDs) are semiconducting inorganic nanocrystals, that have garnered interest in biological and medical spheres due, to their potential benefits in biomedical imaging and drug-delivery systems. Indium phosphide QDs...
4.
James D, Green S, Molica S, Allsup D
Case Rep Hematol
. 2024 Nov;
2024:1813512.
PMID: 39583986
The coexistence of chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) in the same patient is exceedingly rare, with only a few cases reported in the literature. Here, we...
5.
Molica S, Allsup D, Giannarelli D
Am J Hematol
. 2024 Jul;
99(10):2041-2044.
PMID: 39041190
No abstract available.
6.
Taynton T, Allsup D, Barlow G
Expert Rev Hematol
. 2024 Jul;
17(9):581-593.
PMID: 39037307
Introduction: The global need for antifungal stewardship is driven by spreading antimicrobial and antifungal resistance. Triazoles are the only oral and relatively well-tolerated class of antifungal medications, and usage is...
7.
Flett L, Abdelatif R, Baz S, Brady S, Corbacho B, Common K, et al.
Trials
. 2024 Jun;
25(1):427.
PMID: 38943201
Background: Acute leukaemias (AL) are life-threatening blood cancers that can be potentially cured with treatment involving myelosuppressive, multiagent, intensive chemotherapy (IC). However, such treatment is associated with a risk of...
8.
Molica S, Shanafelt T, Allsup D, Giannarelli D
Cancers (Basel)
. 2024 Mar;
16(6).
PMID: 38539420
To assess the impact of first-line treatment with targeted agents (TAs) or fludarabine, cyclophosphamide, and rituximab (FCR)-based chemo-immunotherapy (CIT) on overall survival (OS) compared to age- and sex-matched individuals in...
9.
Molica S, Rossi M, Allsup D
Expert Opin Biol Ther
. 2024 Feb;
24(1-2):1-5.
PMID: 38343083
No abstract available.
10.
Molica S, Shanafelt T, Allsup D, Giannarelli D
Am J Hematol
. 2023 Dec;
99(3):480-483.
PMID: 38100222
Pooled analysis of six mature phase 3 trials (RESONATE2, ILLUMINATE, ALLIANCE041202, ELEVATE-TN, CLL14, and GLOW) evaluating Bruton's tyrosine kinase inhibitors (BTKis) and venetoclax-based treatments suggests that these agents have reduced...